国际移植与血液净化杂志
國際移植與血液淨化雜誌
국제이식여혈액정화잡지
INTERNATIONAL JOURNAL OF TRANSPLANTATION AND HEMOPURIFICATION
2012年
3期
22-25
,共4页
血浆纤溶酶原激活物抑制物%基质金属蛋白酶%糖尿病肾病
血漿纖溶酶原激活物抑製物%基質金屬蛋白酶%糖尿病腎病
혈장섬용매원격활물억제물%기질금속단백매%당뇨병신병
Plasminogen activator inhibitor-1%Matrix metalloproteinase-2%Diabetic nephropathy
目的 探讨2型糖尿病及糖尿病肾病患者血清基质金属蛋白酶水平的变化及其相关影响因素.方法 选取2型糖尿病患者94例,其中2型糖尿病无蛋白尿组患者37例；微量蛋白尿组(尿白蛋白/肌酐为30 ～ 300 mg/g)27例；显著蛋白尿组患者(尿白蛋白/肌酐＞300mg/g)30例.健康体检者32名作为对照组.所有检测对象于清晨空腹抽肘静脉血,应用酶联免疫吸附法测定血清基质金属蛋白酶2及血浆纤溶酶原激活物抑制物1.结果 (1)微量蛋白尿组患者血清基质金属蛋白酶2水平为(4.3±4.1)μg/L,显著蛋白尿组患者为(4.6±4.1)μg/L,与正常对照组[2.8±0.4)μg/L]比较差异有统计学意义(P＜0.05)；(2)微量蛋白尿组患者血浆纤溶酶原激活物抑制物1水平为(69±19)μg/L,显著蛋白尿组患者为(69±18)μg/L,与正常对照组[(52±30)μg/L]比较差异有统计学意义(P＜0.05)；(3)相关分析结果表明,血清基质金属蛋白酶2与血浆纤溶酶原激活物抑制物1水平无相关(r =0.077,P=0.468)；(4)在2型糖尿病患者中血清基质金属蛋白酶2水平与尿素氮、肌酐水平相关(r分别为0.370及0.468,P分别为0.00、0.000),血浆纤溶酶原激活物抑制物1水平与空腹血糖、甘油三酯、高密度脂蛋白、尿酸呈正相关(r分别为0.196、0.342、-0.167、0.203,P分别为0.004、0.000、0.016、0.003).结论 2型糖尿病合并蛋白尿患者血清基质金属蛋白酶2及血浆纤溶酶原激活物抑制物1水平升高,是2型糖尿病患者合并肾病的危险因素.
目的 探討2型糖尿病及糖尿病腎病患者血清基質金屬蛋白酶水平的變化及其相關影響因素.方法 選取2型糖尿病患者94例,其中2型糖尿病無蛋白尿組患者37例；微量蛋白尿組(尿白蛋白/肌酐為30 ～ 300 mg/g)27例；顯著蛋白尿組患者(尿白蛋白/肌酐＞300mg/g)30例.健康體檢者32名作為對照組.所有檢測對象于清晨空腹抽肘靜脈血,應用酶聯免疫吸附法測定血清基質金屬蛋白酶2及血漿纖溶酶原激活物抑製物1.結果 (1)微量蛋白尿組患者血清基質金屬蛋白酶2水平為(4.3±4.1)μg/L,顯著蛋白尿組患者為(4.6±4.1)μg/L,與正常對照組[2.8±0.4)μg/L]比較差異有統計學意義(P＜0.05)；(2)微量蛋白尿組患者血漿纖溶酶原激活物抑製物1水平為(69±19)μg/L,顯著蛋白尿組患者為(69±18)μg/L,與正常對照組[(52±30)μg/L]比較差異有統計學意義(P＜0.05)；(3)相關分析結果錶明,血清基質金屬蛋白酶2與血漿纖溶酶原激活物抑製物1水平無相關(r =0.077,P=0.468)；(4)在2型糖尿病患者中血清基質金屬蛋白酶2水平與尿素氮、肌酐水平相關(r分彆為0.370及0.468,P分彆為0.00、0.000),血漿纖溶酶原激活物抑製物1水平與空腹血糖、甘油三酯、高密度脂蛋白、尿痠呈正相關(r分彆為0.196、0.342、-0.167、0.203,P分彆為0.004、0.000、0.016、0.003).結論 2型糖尿病閤併蛋白尿患者血清基質金屬蛋白酶2及血漿纖溶酶原激活物抑製物1水平升高,是2型糖尿病患者閤併腎病的危險因素.
목적 탐토2형당뇨병급당뇨병신병환자혈청기질금속단백매수평적변화급기상관영향인소.방법 선취2형당뇨병환자94례,기중2형당뇨병무단백뇨조환자37례；미량단백뇨조(뇨백단백/기항위30 ～ 300 mg/g)27례；현저단백뇨조환자(뇨백단백/기항＞300mg/g)30례.건강체검자32명작위대조조.소유검측대상우청신공복추주정맥혈,응용매련면역흡부법측정혈청기질금속단백매2급혈장섬용매원격활물억제물1.결과 (1)미량단백뇨조환자혈청기질금속단백매2수평위(4.3±4.1)μg/L,현저단백뇨조환자위(4.6±4.1)μg/L,여정상대조조[2.8±0.4)μg/L]비교차이유통계학의의(P＜0.05)；(2)미량단백뇨조환자혈장섬용매원격활물억제물1수평위(69±19)μg/L,현저단백뇨조환자위(69±18)μg/L,여정상대조조[(52±30)μg/L]비교차이유통계학의의(P＜0.05)；(3)상관분석결과표명,혈청기질금속단백매2여혈장섬용매원격활물억제물1수평무상관(r =0.077,P=0.468)；(4)재2형당뇨병환자중혈청기질금속단백매2수평여뇨소담、기항수평상관(r분별위0.370급0.468,P분별위0.00、0.000),혈장섬용매원격활물억제물1수평여공복혈당、감유삼지、고밀도지단백、뇨산정정상관(r분별위0.196、0.342、-0.167、0.203,P분별위0.004、0.000、0.016、0.003).결론 2형당뇨병합병단백뇨환자혈청기질금속단백매2급혈장섬용매원격활물억제물1수평승고,시2형당뇨병환자합병신병적위험인소.
Objective In this study,plasma plasminogen activator inhibitor-1(PAI-1) and matxixmetalloproteinase 2(MMP-2) level of type 2 diabetes was measured,which would be helpful to deeply under-stand the pathophysiological mechanism of type 2 diabetic nephropathy.Methods According to the stan-dards of diabetic diagnosis and typing put forward by ADA in 1997,a total of 94 unrelated patients with type2 diabetes were randomly recruited in the study.These patients were further divided into type 2 diabetes withand without nephropathy groups according to their A/C.At the same time 32 healthy controls were selectedfrom population for regular physical examination in our hospital.The levels of MMP-2 and PAI-I were mea-sured by enzyme linked immunosorbent assay(ELISA).Results (1)The plasma MMP-2 level in microalbu-minuria diabetes nephropathy and predominant proteinuria diabetes nephropathy group is(4.3 ± 4.1 )μg/L,(4.6 ± 4.1 )μg/L,which is higher than that in healthy controls(2.8 ± 0.4)μg/L( P＜ 0.05) ; (2)Theplasma PAI-I level in microalbuninuria diabetes nephropathy and predominant proteinuria diabetes nephropa-thy group is(69 ± 19) μg/L,(69 + 18)μg/L,which is higher than that in healthy controls(52 + 30) μg/L( P ＜ 0.05 ) ; (3) The level of plasma PAI- 1 is not related to the level of MMP-2; ( 4 ) In the type 2 diabetesnephropathy,the level of plasma MMP-2 is related to the level of urea nitrogen、Creatinine,the level ofplasma PAI-1 is related to the level of fasting glucose,Tfiglycefides、high density lipoprotein,Uric acid.Conclusion In the type 2 diabetes nephropathy patients,the level of PAI-1 and MMP-2 is higher and thehigher level of PAI-1 and MMP-2 are risk factor of type 2 diabetes nephropathy.
